HC Wainwright Reiterates “Buy” Rating for BioLineRx (NASDAQ:BLRX)

BioLineRx (NASDAQ:BLRX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $21.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com upgraded BioLineRx to a “sell” rating in a report on Friday, April 12th.

BioLineRx Trading Up 3.0 %

NASDAQ:BLRX opened at $0.64 on Wednesday. BioLineRx has a fifty-two week low of $0.61 and a fifty-two week high of $2.53. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.53 and a quick ratio of 1.47. The stock has a market capitalization of $51.17 million, a PE ratio of -0.71 and a beta of 1.38. The business’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.34.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter last year, the firm earned ($0.09) EPS. Sell-side analysts expect that BioLineRx will post -1.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioLineRx

A number of hedge funds and other institutional investors have recently bought and sold shares of BLRX. Renaissance Technologies LLC raised its position in BioLineRx by 377.6% in the 1st quarter. Renaissance Technologies LLC now owns 67,346 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 53,246 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of BioLineRx during the 1st quarter worth approximately $178,000. LPL Financial LLC increased its position in shares of BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 71,134 shares during the last quarter. Envestnet Asset Management Inc. acquired a new position in shares of BioLineRx during the 1st quarter worth approximately $88,000. Finally, Geneos Wealth Management Inc. increased its position in shares of BioLineRx by 72.3% during the 3rd quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 17,000 shares during the last quarter. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.